Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma

NCT01811368 is registered in ClinicalTrials.gov with Joseph Tuscano as lead sponsor.

NCT NCT01811368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01811368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma
Lead sponsor
Joseph Tuscano
Phase
Phase 2
Overall status
Unknown status
Start date
March 12, 2013
Completion date
December 31, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory non hodgkin lymphoma, relapsed non hodgkin lymphoma